Co-treatment of birinapant with TRAIL synergistically induces apoptosis by downregulating cFLIP(L) in MDA-MB-453 cell lines
Open Access
- 1 December 2020
- journal article
- research article
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 533 (3) , 289-295
Abstract
No abstract availableKeywords
Funding Information
- National Research Foundation of Korea
- Ministry of Science and ICT of Korea (NRF-2017M3A9B5060881, NRF- 2017M3C9A5028693)
- Chungnam National University
- Korea Research Institute of Bioscience and Biotechnology
This publication has 32 references indexed in Scilit:
- p53 mutations in cancerNature Cell Biology, 2013
- Smac mimetic Birinapant induces apoptosis and enhances TRAIL potency in inflammatory breast cancer cells in an IAP-dependent and TNF-α-independent mechanismBreast Cancer Research and Treatment, 2012
- Biology, Metastatic Patterns, and Treatment of Patients with Triple-Negative Breast CancerClinical Breast Cancer, 2009
- Inherited Susceptibility to Common CancersNew England Journal of Medicine, 2008
- Molecular Classification and Molecular Forecasting of Breast Cancer: Ready for Clinical Application?Journal of Clinical Oncology, 2005
- Mechanisms of resistance to TRAIL-induced apoptosis in cancerCancer Gene Therapy, 2004
- FLIP Protein and TRAIL-Induced Apoptosis2004
- Resistance to TRAIL-induced apoptosis in primitive neuroectodermal brain tumor cells correlates with a loss of caspase-8 expressionOncogene, 2000
- Emerging roles of caspase-3 in apoptosisCell Death & Differentiation, 1999
- Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patientsNature Medicine, 1996